
Faeth Therapeutics (FTH) announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche to evaluate PIKTOR in combination with the investigational medicine giredestrant
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| FTH | Faeth Therapeutics | 9.04 | 0.50 | 5.87% |
| Name | Price | % Change | |
|---|---|---|---|
| $9.04 | +5.87% |

Faeth Therapeutics (FTH) announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche to evaluate PIKTOR in combination with the investigational medicine giredestrant

Citi raised the firm’s price target on Faeth Therapeutics (FTH) to $60 from $55 and keeps a Buy rating on the shares. The firm views the PIK-201 topline dataset as

Lucid Capital views the selloff today in shares of Faeth Therapeutics (FTH) following the company’s Phase 2 Piktor data in patients with advanced endometrioid endometrial cancer. The company reported positive

Faeth Therapeutics (FTH) reported encouraging PIK-201 endometrial cancer data, with a 33% confirmed ORR, bull-case PFS results and favorable tolerability supporting PIKTOR’s differentiated safety profile and broader breast cancer opportunity

After Faeth Therapeutics (FTH) announced preliminary topline results from its Phase 2 PIK-201 trial evaluating serabelisib plus sapanisertib in combination with paclitaxel in advanced PAM-pathway-altered endometrioid endometrial cancer, H.C. Wainwright

An update from Faeth Therapeutics ( ($FTH) ) is now available. On November 9, 2026, Faeth Therapeutics made available presentation data from its Phase 2 PIK-201 trial of investigational PIKTOR,

New option listings for November 9th include Mini Russell 2000 Index 1/10th (.MRTBX), Nasdaq-100 Binary Options Reference Index (.NDXB), Faeth Therapeutics, Inc (FTH), and Iqm Quantum Computers Oyj (IQMX). Option

The latest announcement is out from Faeth Therapeutics ( ($FTH) ). On November 9, 2026, Faeth reported preliminary topline Phase 2 results for PIKTOR combined with paclitaxel in 42 patients

Faeth Therapeutics (FTH) announced topline clinical data from its Phase 2 trial of Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid

Guggenheim analyst Brad Canino lowered the firm’s price target on Faeth Therapeutics (FTH) to $69 from $70 and keeps a Buy rating on the shares as the firm adjusted estimates
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Assigned | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Initiated | Oct 15, 2026 | ||||
| buy | Initiated | Oct 15, 2026 | ||||
| buy | Initiated | Sep 9, 2026 | ||||
| buy | Initiated | Aug 21, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $233.63M | $-0.85 | $0.00 | 0.02 | -0.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.